Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Exploration of HCP1803 in Essential Hypertension
NCT04959305Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HCP-1803 in essential hypertension (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change from baseline in sitting systolic blood pressure at 8 weeks. Started Apr 2021; status: completed.
02
Drugs
HCP-1803
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT04959305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959305.